Mr. Vohra laboured for Eicher Motors, and Dr. Reddy’s after earning degrees in engineering, management, and accounting.
He has a remarkable career in generics, accounting, marketing and business, supply – chain management and management, among other businesses and responsibilities, as a result of his past jobs in India and the United States.
Mr. Vohra formerly served as Cipla’s Global Director Of Operations and Global Finance Department.
Among his other accomplishments as CFO, he successfully integrated Cipla’s investments in the United States, clearing the door for Cipla to expand its business in the United States.
He has served as the company’s MD and CEO and Pharmaceuticals after earning advanced degrees, management, and economics.
He has a renowned lengthy career years and years, with comprehensive experience and insight of numerous sectors of the global drug company, thanks to previous jobs in India and the United States.
Table of Contents
Quick facts:
Born: 1978
Nationality: Indian
Citizenship: India
Education: MVA
Occupation: Businessman
Title: CEO of Cipla
Spouse: Married
Children: nill
Net worth: 4 crore annually
Strategy defining Growth:
Cipla’s strategic development, identifying and trying to execute Cipla’s roadmap to keep the momentum going in the domestic market while Increasing its visibility in additional places geographic areas.
Aligning Two primary focal areas, competence enhancement, and going to build the leadership credibility have been Mr Vohra’s major considerations as Cipla’s MD and CEO.
Mr. Vohra is a person who believes in the ability of fluid business strategies, disruptive technology, content knowledge, and a new generation of employees to transform the experience for customers.
Formation of Cipla Ltd:
The business focuses on novel medicine combinations and sells a wide range of generic drugs. There are prescription pharmaceuticals, drug substances, animal foods, and insecticides on hand.
Also provided are beverages, baked foods, oral hygiene products, cleaners, house odor neutralizer, and home healthcare.
Outside of India, the company earns over 55 percent of its total revenue. It has 5,500 items registered in different nations.
Cipla manufactures medications for the treatment of cancer, Alzheimer’s disease, arthritis, cardiovascular disease, and other diseases. It also sells medications that prevent AIDS from being passed down from mother to kid.
The company is providing product and preparation and analysis advice, as well as plant appraisal and plant hardware supply.
Given being informed of Subhanu’s personal circumstances, we support his choice to quit Cipla, stated Dr. Y K Hamied, Cipla’s non-executive chairperson. We appreciate his leadership throughout the last three years, as well as his willingness to assist his successors with any changeover needs in the coming months.
We are ecstatic to see two young leaders, Umang take on greater responsibility at Cipla. Both have deserved their current roles as a result of their old management and effectiveness. Samina’s promotion also demonstrates the presenter’s family’s protracted devotion to Cipla.
Realigning it, supplementing functionality, and going to build the leadership credibility have already been ohra’s top priorities.
